Trial Outcomes & Findings for COVID-19, Chronic Adaptation and Response to Exercise (COVID-CARE) (NCT NCT04595773)

Last Updated: 2026-05-12

Results Overview

The 6-minute walk test (6MWT) is a measure of physical capacity and subjects are instructed to walk as far as possible around a pre-measured walking course over a time period of six minutes. The 6-minute walk test distance (6MWD) is the total distance walked in meters during the 6MWT and greater distance walked means better physical capacity. This outcome is reported as the difference between time-points (post- minus pre-10 weeks).

Recruitment status

ACTIVE_NOT_RECRUITING

Study phase

Target enrollment

48 participants

Primary outcome timeframe

Before and after 10 weeks

Results posted on

2026-05-12

Participant Flow

48 participants who consented to the study * 40 participants were randomized to study interventions * 6 participants were screen failure * One participant withdrew before randomization * One participant withdrew after randomization and prior to start of intervention

Participant milestones

Participant milestones
Measure	Aerobic Exercise Intervention (AET+) Participants post-acute infection from SARS-CoV-2 with persistent sequelae performed aerobic exercise three times a week plus weekly education for 10 weeks.	Control Group (CON) Participants post-acute infection from SARS-CoV-2 with persistent sequelae performed weekly education for 10 weeks, then crossed over to perform aerobic exercise three times a week for 10 weeks.
Period 1 - Week 1-10 STARTED	20	20
Period 1 - Week 1-10 COMPLETED	20	20
Period 1 - Week 1-10 NOT COMPLETED	0	0
Period 2 - Week 11- 20 STARTED	0	20
Period 2 - Week 11- 20 COMPLETED	0	19
Period 2 - Week 11- 20 NOT COMPLETED	0	1

Reasons for withdrawal

Reasons for withdrawal
Measure	Aerobic Exercise Intervention (AET+) Participants post-acute infection from SARS-CoV-2 with persistent sequelae performed aerobic exercise three times a week plus weekly education for 10 weeks.	Control Group (CON) Participants post-acute infection from SARS-CoV-2 with persistent sequelae performed weekly education for 10 weeks, then crossed over to perform aerobic exercise three times a week for 10 weeks.
Period 2 - Week 11- 20 Physician Decision	0	1

Baseline Characteristics

COVID-19, Chronic Adaptation and Response to Exercise (COVID-CARE)

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Control Group (CON) n=20 Participants Participants post-acute infection from SARS-CoV-2 with persistent sequelae performed weekly education for 10 weeks, then crossed over to perform aerobic exercise three times a week for 10 weeks.	Total n=40 Participants Total of all reporting groups	Aerobic Exercise Intervention (AET+) n=20 Participants Participants post-acute infection from SARS-CoV-2 with persistent sequelae performed aerobic exercise three times a week plus weekly education for 10 weeks.
Age, Categorical <=18 years	0 Participants n=504 Participants	0 Participants n=2016 Participants	0 Participants n=1512 Participants
Age, Categorical Between 18 and 65 years	20 Participants n=504 Participants	38 Participants n=2016 Participants	18 Participants n=1512 Participants
Age, Categorical >=65 years	0 Participants n=504 Participants	2 Participants n=2016 Participants	2 Participants n=1512 Participants
Sex: Female, Male Female	16 Participants n=504 Participants	31 Participants n=2016 Participants	15 Participants n=1512 Participants
Sex: Female, Male Male	4 Participants n=504 Participants	9 Participants n=2016 Participants	5 Participants n=1512 Participants
Ethnicity (NIH/OMB) Hispanic or Latino	3 Participants n=504 Participants	7 Participants n=2016 Participants	4 Participants n=1512 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	17 Participants n=504 Participants	33 Participants n=2016 Participants	16 Participants n=1512 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	0 Participants n=504 Participants	0 Participants n=2016 Participants	0 Participants n=1512 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants n=504 Participants	0 Participants n=2016 Participants	0 Participants n=1512 Participants
Race (NIH/OMB) Asian	3 Participants n=504 Participants	4 Participants n=2016 Participants	1 Participants n=1512 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants n=504 Participants	0 Participants n=2016 Participants	0 Participants n=1512 Participants
Race (NIH/OMB) Black or African American	3 Participants n=504 Participants	5 Participants n=2016 Participants	2 Participants n=1512 Participants
Race (NIH/OMB) White	13 Participants n=504 Participants	29 Participants n=2016 Participants	16 Participants n=1512 Participants
Race (NIH/OMB) More than one race	1 Participants n=504 Participants	2 Participants n=2016 Participants	1 Participants n=1512 Participants
Race (NIH/OMB) Unknown or Not Reported	0 Participants n=504 Participants	0 Participants n=2016 Participants	0 Participants n=1512 Participants

PRIMARY outcome

Timeframe: Before and after 10 weeks

Population: All participants who completed the first 10 weeks of the study intervention.

Outcome measures

Outcome measures
Measure	Aerobic Exercise Intervention (AET+) n=20 Participants Participants post-acute infection from SARS-CoV-2 with persistent sequelae performed aerobic exercise three times a week plus weekly education for 10 weeks.	Control Group (CON) n=20 Participants Participants post-acute infection from SARS-CoV-2 with persistent sequelae performed weekly education for 10 weeks.
Change in 6-minute Walk Test Distance (6MWD)	57.7 Meters Standard Deviation 44.67	18.4 Meters Standard Deviation 25.67

Adverse Events

Aerobic Exercise Intervention (AET+)

Serious events: 0 serious events

Other events: 16 other events

Deaths: 0 deaths

Control Group (CON) - Education

Serious events: 0 serious events

Other events: 11 other events

Deaths: 0 deaths

Control Group (CON) - Exercise

Serious events: 0 serious events

Other events: 11 other events

Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Additional Information

Dr. Leighton Chan

National Institutes of Health Clinical Center (NIH CC)

Phone: 1 301 496 4300

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee
Publication restrictions are in place

Other adverse events
Measure	Aerobic Exercise Intervention (AET+) n=20 participants at risk Participants post-acute infection from SARS-CoV-2 with persistent sequelae performed aerobic exercise three times a week plus weekly education for 10 weeks.	Control Group (CON) - Education n=20 participants at risk Participants post-acute infection from SARS-CoV-2 with persistent sequelae performed weekly education for 10 weeks.	Control Group (CON) - Exercise n=20 participants at risk Participants post-acute infection from SARS-CoV-2 with persistent sequelae performed aerobic exercise three times a week for 10 weeks.
Ear and labyrinth disorders Vertigo	0.00% 0/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.	5.0% 1/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.	0.00% 0/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.
Gastrointestinal disorders Abdominal pain upper	0.00% 0/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.	5.0% 1/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.	0.00% 0/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.
Gastrointestinal disorders Diarrhoea	10.0% 2/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.	0.00% 0/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.	0.00% 0/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.
Investigations Electrocardiogram abnormal	0.00% 0/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.	5.0% 1/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.	0.00% 0/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.
Investigations Imaging procedure	0.00% 0/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.	5.0% 1/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.	0.00% 0/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.
Gastrointestinal disorders Irritable bowel syndrome	0.00% 0/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.	0.00% 0/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.	5.0% 1/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.
General disorders and administration site conditions Fatigue	10.0% 2/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.	0.00% 0/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.	5.0% 1/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.
General disorders and administration site conditions Influenza like illness	0.00% 0/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.	5.0% 1/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.	0.00% 0/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.
General disorders and administration site conditions Non-cardiac chest pain	0.00% 0/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.	0.00% 0/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.	5.0% 1/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.
Nervous system disorders Headache	5.0% 1/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.	0.00% 0/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.	0.00% 0/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.
Blood and lymphatic system disorders Lymphadenopathy	0.00% 0/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.	5.0% 1/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.	0.00% 0/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.
Cardiac disorders Atrial fibrillation	0.00% 0/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.	0.00% 0/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.	5.0% 1/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.
General disorders and administration site conditions Pain	5.0% 1/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.	0.00% 0/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.	0.00% 0/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.
Infections and infestations Otitis media	0.00% 0/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.	0.00% 0/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.	5.0% 1/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.
Infections and infestations Otitis media acute	5.0% 1/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.	0.00% 0/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.	0.00% 0/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.
Infections and infestations Skin infection	0.00% 0/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.	0.00% 0/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.	5.0% 1/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.
Infections and infestations Urinary tract infection	5.0% 1/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.	0.00% 0/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.	0.00% 0/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.
Injury, poisoning and procedural complications Fall	0.00% 0/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.	5.0% 1/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.	0.00% 0/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.
Injury, poisoning and procedural complications Vaccination complication	20.0% 4/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.	10.0% 2/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.	0.00% 0/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.
Investigations Coronavirus test positive	15.0% 3/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.	10.0% 2/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.	15.0% 3/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.
Musculoskeletal and connective tissue disorders Arthralgia	5.0% 1/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.	0.00% 0/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.	5.0% 1/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.
Musculoskeletal and connective tissue disorders Muscle spasms	0.00% 0/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.	0.00% 0/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.	5.0% 1/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.
Musculoskeletal and connective tissue disorders Myalgia	5.0% 1/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.	0.00% 0/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.	5.0% 1/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Ovarian cyst	0.00% 0/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.	5.0% 1/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.	0.00% 0/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.
Psychiatric disorders Anxiety	10.0% 2/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.	0.00% 0/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.	0.00% 0/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.
Psychiatric disorders Depression	5.0% 1/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.	0.00% 0/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.	0.00% 0/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.
Respiratory, thoracic and mediastinal disorders Cough	5.0% 1/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.	0.00% 0/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.	5.0% 1/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.
Respiratory, thoracic and mediastinal disorders Dyspnoea	5.0% 1/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.	0.00% 0/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.	0.00% 0/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.
Respiratory, thoracic and mediastinal disorders Nasal congestion	0.00% 0/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.	5.0% 1/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.	0.00% 0/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.
Respiratory, thoracic and mediastinal disorders Pharyngitis	0.00% 0/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.	5.0% 1/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.	0.00% 0/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.
Respiratory, thoracic and mediastinal disorders Pharyngitis streptococcal	5.0% 1/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.	5.0% 1/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.	0.00% 0/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.
Respiratory, thoracic and mediastinal disorders Rhinitis	5.0% 1/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.	0.00% 0/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.	5.0% 1/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.
Respiratory, thoracic and mediastinal disorders Rhinitis allergic	0.00% 0/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.	5.0% 1/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.	0.00% 0/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.
Respiratory, thoracic and mediastinal disorders Sinusitis	5.0% 1/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.	0.00% 0/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.	0.00% 0/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.
Respiratory, thoracic and mediastinal disorders Upper respiratory tract infection	15.0% 3/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.	5.0% 1/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.	10.0% 2/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.
Skin and subcutaneous tissue disorders Dermatitis allergic	5.0% 1/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.	0.00% 0/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.	0.00% 0/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.
Skin and subcutaneous tissue disorders Rash	5.0% 1/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.	0.00% 0/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.	0.00% 0/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.
Skin and subcutaneous tissue disorders Skin irritation	0.00% 0/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.	5.0% 1/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.	0.00% 0/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.
Vascular disorders Hypotension	0.00% 0/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.	0.00% 0/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.	5.0% 1/20 • Start of study to end of on-site study completion, ~3 months for Aerobic Exercise Intervention (AET+) and ~6 months for Control Group (CON) Adverse events (AEs) were defined as any symptom or condition occurring after study initiation that was not present at baseline. For conditions or symptoms present at baseline, events were reported as adverse events only if there was a worsening in severity or an increase in frequency during the study period.